HIV disease among substance users: treatment issues

Sande's HIV/AIDS Medicine: Medical Management of AIDS 2013

Volumn , Issue , 2012, Pages 537-549

  Bruce, R Douglas ^a   Altice, Frederick L ^a   Friedland, Gerald ^b,c  

^a YALE UNIVERSITY   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Columbia University ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902038452     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0695-2.00040-7     Document Type: Chapter

References (59)

1. N.K. Morojele, J.S. Brook and M.A. Kachieng'a (2006) Perceptions of sexual risk behaviours and substance abuse among adolescents in South Africa: a qualitative investigation. AIDS Care 18 215-219.
2. UNAIDS (2002) Report on the Global HIV/AIDS Epidemic. UNAIDS (Ed.) United Nations
3. G.J. Hart, C. Sonnex, A. Petherick, et al. (1989) Risk behaviours for HIV infection among injecting drug users attending a drug dependency clinic. BMJ 298 1081-1083.
4. M.L. Williams, S.A. McCurdy, A.M. Bowen, et al. (2009) HIV seroprevalence in a sample of Tanzanian intravenous drug users. AIDS Educ Prev 21 474-483.
5. F.L. Altice, A. Kamarulzaman, V.V. Soriano, et al. (2010) Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet 376 59-79.
6. P. Alcabes and G.H. Friedland (1995) Injection drug use and human immunodeficiency virus infection. Clin Infect Dis 20 1467-1479.
7. A.H. Anis, D. Guh, R.S. Hogg, et al. (2000) The cost effectiveness of antiretroviral regimens for the treatment of HIV/AIDS. Pharmacoeconomics 18 393-404.
8. A.H. Kaplan, A. Scheyett and C.E. Golin (2005) HIV and stigma: analysis and research program. Curr HIV/AIDS Rep 2 184-188.
9. T.F. Kresina, L. Eldred, R.D. Bruce and H. Francis (2005) Integration of pharmacotherapy for opioid addiction into HIV primary care for HIV/hepatitis C virus-co-infected patients. AIDS 19(Suppl. 3), S221-226.
10. A. Urbina and K. Jones (2004) Crystal methamphetamine, its analogues, and HIV infection: medical and psychiatric aspects of a new epidemic. Clin Infect Dis 38 890-894.
11. G. Chander, S. Himelhoch and R.D. Moore (2006) Substance abuse and psychiatric disorders in HIV-positive patients: epidemiology and impact on antiretroviral therapy. Drugs 66 769-789.
12. N.K. Morojele, M.A. Kachieng'a, E. Mokoko, et al. (2006) Alcohol use and sexual behaviour among risky drinkers and bar and shebeen patrons in Gauteng province, South Africa. Soc Sci Med 62 217-227.
13. C.S. Hendershot, S.A. Stoner, W.H. George and J. Norris (2007) Alcohol use, expectancies, and sexual sensation seeking as correlates of HIV risk behavior in heterosexual young adults. Psychol Addict Behav 21 365-372.
14. M.M. Azar, S.A. Springer, J.P. Meyer and F.L. Altice (2010) A systematic review of the impact of alcohol use disorders on HIV treatment outcomes, adherence to antiretroviral therapy and health care utilization. Drug Alcohol Depend 112 178-193.
15. F.L. Altice, R.D. Bruce, G.M. Lucas, et al. (2011) HIV treatment outcomes among HIV-infected, opioid-dependent patients receiving buprenorphine/naloxone treatment within HIV clinical care settings: results from a multisite study. J Acquir Immune Defic Syndr 56(Suppl. 1), S22-S32.
16. D. Smith-Rohrberg, R.D. Bruce and F.L. Altice (2004) Review of corrections based therapy for opiate-dependent patients: implications for buprenorphine treatment among correctional populations. J Drug Issues 34 451-480.
17. K. Dolan, W. Hall and A. Wodak (1996) Methadone maintenance reduces injecting in prison. BMJ 312 1162.
18. E. Donny, S. Walsh, G. Bigelow, et al. (2002) High-dose methadone produces superior opioid blockade and comparable withdrawal suppression to lower doses in opioid-dependent humans. Psychopharmacology 161 202-212.
19. P.J. Fudala, T.P. Bridge, S. Herbert, et al. (2003) Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med 349 949-958.
20. J.B. Murray (1998) Effectiveness of methadone maintenance for heroin addiction. Psychol Rep 83 295-302.
21. D.S. Metzger, G.E. Woody and C.P. O'Brien (2010) Drug treatment as HIV prevention: a research update. J Acquir Immune Defic Syndr 55(Suppl. 1), S32-S36.
22. D.S. Metzger, G.E. Woody, A.T. McLellan, et al. (1993) Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr 6 1049-1056.
23. V.P. Dole and M. Nyswander (1965) A medical treatment for diacetylmorphine (heroin) addiction. A clinical trial with methadone hydrochloride. JAMA 193 646-650.
24. R.D. Bruce (2010) Methadone as HIV prevention: high volume methadone sites to decrease HIV incidence rates in resource limited settings. Int J Drug Policy 21 122-124.
25. T. Kerr, A. Wodak, R. Elliott, et al. (2004) Opioid substitution and HIV/AIDS treatment and prevention. Lancet 364 1918-1919.
26. C.M. Doran, M. Shanahan, R.P. Mattick, et al. (2003) Buprenorphine versus methadone maintenance: a cost-effectiveness analysis. Drug Alcohol Depend 71 295-302.
27. R.E. Johnson, M.A. Chutuape, E.C. Strain, et al. (2000) A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence. N Engl J Med 343 1290-1297.
28. A. Liguori, W.H. Morse and J. Bergman (1996) Respiratory effects of opioid full and partial agonists in rhesus monkeys. J Pharmacol Exp Ther 277 462-472.
29. N. Clark, N. Lintzeris, A. Gijsbers, et al. (2002) LAAM maintenance vs methadone maintenance for heroin dependence. Cochrane Database Syst Rev CD002210
30. R.E. Johnson, T. Eissenberg, M.L. Stitzer, et al. (1995) Buprenorphine treatment of opioid dependence: clinical trial of daily versus alternate-day dosing. Drug Alcohol Depend 40 27-35.
31. R.D. Bruce, S. Dvoryak, L. Sylla and F.L. Altice (2007) HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. Int J Drug Policy 18 326-328.
32. S. Basu, D. Smith-Rohrberg, R.D. Bruce and F.L. Altice (2006) Models for integrating buprenorphine therapy into the primary HIV care setting. Clin Infect Dis 42 716-721.
33. R.A. Greenstein, B.D. Evans, A.T. McLellan and C.P. O'Brien (1983) Predictors of favorable outcome following naltrexone treatment. Drug Alcohol Depend 12 173-180.
34. R.S. Schottenfeld, M.C. Chawarski and M. Mazlan (2008) Maintenance treatment with buprenorphine and naltrexone for heroin dependence in Malaysia: a randomised, double-blind, placebo-controlled trial. Lancet 371 2192-2200.
35. I.L. Petrakis, K.M. Carroll, C. Nich, et al. (2000) Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95 219-228.
36. A. Madan, A. Parkinson and M.D. Faiman (1998) Identification of the human P-450 enzymes responsible for the sulfoxidation and thiono-oxidation of diethyldithiocarbamate methyl ester: role of P-450 enzymes in disulfiram bioactivation. Alcohol Clin Exp Res 22 1212-1219.
37. S. Shoptaw, A. Huber, J. Peck, et al. (2006) Randomized, placebo-controlled trial of sertraline and contingency management for the treatment of methamphetamine dependence. Drug Alcohol Depend 85 12-18.
38. J.A. Peck, C.J. Reback, X. Yang, et al. (2005) Sustained reductions in drug use and depression symptoms from treatment for drug abuse in methamphetamine-dependent gay and bisexual men. J Urban Health 82 i100-108.
39. R.F. Anton, S.S. O'Malley, D.A. Ciraulo, et al. (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295 2003-2017.
40. T. Town, J. Schinka, J. Tan and M. Mullan (2000) The opioid receptor system and alcoholism: a genetic perspective. Eur J Pharmacol 410 243-248.
41. S.S. O'Malley, A.J. Jaffe, G. Chang, et al. (1992) Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Arch Gen Psychiatry 49 881-887.
42. S. Basu, L.A. Chwastiak and R.D. Bruce (2005) Clinical management of depression and anxiety in HIV-infected adults. AIDS 19 2057-2067.
43. S.C. Kalichman and D. Rompa (2003) HIV treatment adherence and unprotected sex practices in people receiving antiretroviral therapy. Sex Transm Infect 79 59-61.
44. R.D. Bruce, F.L. Altice, M.N. Gourevitch and G.H. Friedland (2006) Pharmacokinetic drug interactions between opioid agonist therapy and antiretroviral medications: implications and management for clinical practice. J Acquir Immune Defic Syndr 41 563-572.
45. E.F. McCance-Katz, P.M. Rainey, G. Friedland, et al. (2001) Effect of opioid dependence pharmacotherapies on zidovudine disposition. Am J Addict 10 296-307.
46. S.M. Clarke, F.M. Mulcahy, J. Tjia, et al. (2001) The pharmacokinetics of methadone in HIV-positive patients receiving the non-nucleoside reverse transcriptase inhibitor efavirenz. Br J Clin Pharmacol 51 213-217.
47. E.F. McCance-Katz, P. Pade, G. Friedland, et al. (2005) Efavirenz is not associated with opiate withdrawal in buprenorphine-maintained individuals. 12th Conference on Retroviruses and Opportunistic Infections Boston, MA: Foundation for Retrovirology and Human Health
48. E.F. McCance-Katz, D.E. Moody, G.D. Morse, et al. (2010) Lack of clinically significant drug interactions between nevirapine and buprenorphine. Am J Addict 19 30-37.
49. S. Clarke, F. Mulcahy, C. Bergin, et al. (2002) Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir. Clin Infect Dis 34 1143-1145.
50. E.F McCance-katz, P.M. Rainey, G. Friedland and P Jatlow (2003) The protease inhibitor lopinavir/ritonavir may produce opiate withdrawal in methadone-maintained patients. Clinical infections Diseases 37 476-482.
51. V. Sekar, F. Tomaka, E. Lefebvre, et al. (2011) Pharmacokinetic interactions between darunavir/ritonavir and opioid maintenance therapy using methadone or buprenorphine/naloxone. J Clin Pharmacol 51 271-278.
52. E. McCance-Katz, P. Pade, G.D. Morse, et al. (2006) Interaction between buprenorphine and atazanavir. College on Problems of Drug Dependence Scottsdale, AZ
53. P. Vergara-Rodriguez, M.J. Tozzi, M. Botsko, et al. (2011) Hepatic safety and lack of antiretroviral interactions with buprenorphine/naloxone in HIV-infected opioid-dependent patients. J Acquir Immune Defic Syndr 56(Suppl. 1), S62-67.
54. R.D. Bruce, F.L. Altice, D.E. Moody, et al. (2009) Pharmacokinetic interactions between buprenorphine/naloxone and tipranavir ritanovir in HIV-negative subjects chronically receiving buprenorphine/naloxone. Drug Alcohol Depend 105 234-239.
55. M.J. Kreek, J.W. Garfield, C.L. Gutjahr and L.M. Giusti (1976) Rifampin-induced methadone withdrawal. N Engl J Med 294 1104-1106.
56. E.F. McCance-Katz, D.E. Moody, S. Prathikanti, et al. (2011) Rifampin, but not rifabutin, may produce opiate withdrawal in buprenorphine-maintained patients. Drug Alcohol Depend [Epub ahead of print]
57. M.N. Cobb, J. Desai, L.S. Brown Jr., et al. (1998) The effect of fluconazole on the clinical pharmacokinetics of methadone. Clin Pharmacol Ther 63 655-662.
58. R. Broadhead, C. Borch, Y. van Hulst, et al. (2003) Safer injection sites in New York City: a utilization survey of injection drug users. J Drug Issues 33 533-538.
59. Centers for Disease Control and Prevention (2001) Compendium of HIV prevention interventions with evidence of effectiveness. National Center for HIV, STD and TB Prevention